Priaxon enters collaboration with GSK on Protein-Protein-Interactions
"Using the strength of its unique drug discovery platform Priaxplore®, Priaxon will develop new small molecule modulators for hard-to-drug PPI targets," said Dr. Juergen Kolb, CEO of Priaxon. "Our collaboration with GSK and its experts provides the resources and the capabilities to drive these programs forward. We are looking forward to working together with the goal to develop small molecule modulators for various protein-protein interaction of high potential."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.